Recently, the anti-angiogenic therapies, such as Avastin (Bevacizumab), have become promising cancer therapies, including those for breast cancer. However, these drugs for the VEGF may generate a variety of serious side effects. To overcome this problem, the CMUH has developed the dual target fusion protein (Endo-CD) treatment. The animal experiments have been completed to determine the concept, and the experiment results show that the Endo-CD is more effective and less toxic than Avastin (Bevacizumab).
In the tumor, cancer stem cells are a small group of cancer cells with resistance of cancer treatment and regeneration of neoplasms. They are regarded as the major obstacle to cancer treatment. In order to address the problem for the resistance of cancer stem cell, the CMUH has developed a novel gene therapy (BikDD) to effectively kill breast cancer stem cells.
The triple-negative breast cancer (i.e., the estrogen receptor, progesterone receptor and ErbB2 receptor low density) accounts for about 15% of all breast cancers. So far there is no effective treatment for such breast cancer. The CMUH has developed a novel therapy to transform the triple-negative breast cancer into the cancer of estrogen receptor-positive (hormone therapy) or ErbB2 receptor-positive (Herceptin-therapy). The treatment can convert the non-target triple-negative breast cancer into the target type breast cancer.
It is now known that many molecular mechanisms / signal transduction networks may lead the cancer progression and metastasis. However, there are differences for these molecular profiles between the patients suffering the same type but different cancer.
The CMUH performs the further researches on the related signal transductions, such as the PI3K / AKT, IKKbeta and ERK in breast cancer, EGFR and RANKL / RANK in oral cancer, and Nrf2 and EGFR in lung cancer, in order to comprehend the drug responses or resistance for various tumors. For these signal transductions, the protein density is also essential in the cancer metastasis, prognosis and relapse. Therefore, understanding and dissecting these signal transductions / molecular mechanisms shall contribute to the development of personalized medicine in the future.
Since the early diagnosis can significantly reduce the lethality of cancer, the CMUH supports a variety of early diagnosis and personalized treatments by developing new medical devices and introducing them into clinical trials. Through the construction of a self-controlled electronics industrial chain for biology and medicine, the CMUH develops the oral cancer hyper-spectral imaging diagnosis system, the early DOS / I breast cancer screening imaging diagnostic system and the lung cancer computer-aided diagnosis system with leading technology and high-value application for early cancer screening, in order to achieve the early treatments.
Through the ultrasonic breast scan to develop ultrasound-based elastography, the tissue elasticity is detected with the waveforms, tissues and resistance to perform the early screening for patients with breast cancer.
The CMUH has also developed the oral cancer hyper-spectrum screening instrument. The protein spectrum information of hyper-spectral images and cancer-related genes are compared to assist the early diagnosis and staging of oral cancer.
For lung cancer, the computed tomography (CT) is still the main instrument in clinical diagnosis and staging at present. Through the instrument, the computerized tumor characteristics with robustness are sought to determine the tumor in the CT images under various screening protocols. The results generated based on these description methods are consistent and support the diagnostic value and significance.